The solution
We undertook 1,300 patient interviews across seven Asian markets (China, Malaysia, Korea, Thailand, Taiwan, Singapore and Hong Kong) recruited from 37 key public sector treatment centres.
The outputs
Limited use of HPV vaccination in the region is due to lack of acceptance and understanding of parents and uncovered necessity for physicians to be more proactive in increasing awareness and advocating for vaccination.
A rigorous research approach, involving key stakeholders early and getting engagement from the Principal Investigators (PI) led to a publication, driving the rest of the medical community to advocate for the healthcare benefits of HPV vaccination.